Haematological malignancies
Gene: SAMD9
The association between mono-allelic variants and disease is well established. Developmental delay is a feature of MIRAGE syndrome.
Bi-allelic variants: in effect only two families reported (founder variant in 5 Jewish Yemenite families, plus one other). Amber for this association.Created: 21 Mar 2022, 6:16 p.m. | Last Modified: 21 Mar 2022, 6:16 p.m.
Panel Version: 0.11687
Mode of inheritance
BOTH monoallelic and biallelic, autosomal or pseudoautosomal
Phenotypes
MIRAGE syndrome, MIM#617053; Tumoral calcinosis, familial, normophosphatemic, MIM#610455; Monosomy 7 myelodysplasia and leukemia syndrome 2, MIM# 619041
Gain of function listed as disease mechanism in regard to MIRAGE syndrome (AD).
I note that SAMD9 is listed as a green gene on MM gene list (AR)- however there is a review questioning whether there is enough evidence for the AR tumoral calcinosis - based on few cases and only two published variants? These variants are noted to be LOF.
SAMD9 is also included on the ID gene list with no review. I have not come across an association with ID or learning concerns - ? remove from ID gene listCreated: 21 Mar 2022, 1:19 p.m. | Last Modified: 21 Mar 2022, 1:19 p.m.
Panel Version: 0.11659
Mode of inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Phenotypes
MIRAGE syndrome, MIM#617053; Tumoral calcinosis, familial, normophosphatemic, MIM#610455; Monosomy 7 myelodysplasia and leukemia syndrome 2, MIM#619041
Publications
gene: SAMD9 was added gene: SAMD9 was added to Haematological malignancies. Sources: Expert Review Green,Victorian Clinical Genetics Services Mode of inheritance for gene: SAMD9 was set to BOTH monoallelic and biallelic, autosomal or pseudoautosomal Publications for gene: SAMD9 were set to 33237688; 32619790; 16960814; 18094730 Phenotypes for gene: SAMD9 were set to MIRAGE syndrome, MIM#617053; Tumoral calcinosis, familial, normophosphatemic, MIM#610455; Monosomy 7 myelodysplasia and leukemia syndrome 2, MIM# 619041